- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Primary hyperaldosteronism.
Displaying page 1 of 1.
EudraCT Number: 2021-003460-27 | Sponsor Protocol Number: 2021-12964 | Start Date*: 2022-01-04 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism | |||||||||||||
Medical condition: Primary Aldosteronism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000051-10 | Sponsor Protocol Number: A091200 | Start Date*: 2008-05-19 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | ||
Full Title: 11C metomidate PET scanning for Conn's syndrome | ||
Medical condition: Primary hyperaldosteronism - Conn's syndrome and bilateral adrenal hyperplasia. Imaging of adrenal lesions using 11C-metomidate PET. Pre-suppression with dexamethasone and/or fludrocortisone to opt... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000919-85 | Sponsor Protocol Number: DP13C201 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:DAMIAN Pharma AG | |||||||||||||
Full Title: DP13 – A Phase II Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period | |||||||||||||
Medical condition: Primary Aldosteronism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005681-13 | Sponsor Protocol Number: CLCI699A2206 | Start Date*: 2008-03-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldo... | |||||||||||||
Medical condition: hypertension artérielle par hyperaldostéronisme primaire | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
